Compare KNRX & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KNRX | BIAF |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9M | 9.2M |
| IPO Year | 2023 | 2022 |
| Metric | KNRX | BIAF |
|---|---|---|
| Price | $1.17 | $7.41 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 26.4K | ★ 7.4M |
| Earning Date | 06-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,900,000.00 |
| Revenue This Year | N/A | $20.95 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 14.49 |
| 52 Week Low | $0.28 | $0.33 |
| 52 Week High | $3.45 | $20.35 |
| Indicator | KNRX | BIAF |
|---|---|---|
| Relative Strength Index (RSI) | 89.37 | 53.72 |
| Support Level | $0.35 | $1.07 |
| Resistance Level | $1.46 | $12.48 |
| Average True Range (ATR) | 0.11 | 1.44 |
| MACD | 0.06 | -0.36 |
| Stochastic Oscillator | 75.71 | 29.69 |
Knorex Ltd is a B2B technology company providing programmatic advertising products and solutions to marketers to streamline and automate their advertising and marketing workflows. The company's product, Knorex XPOSM, is a self-service, enterprise-grade cloud platform with a suite of advertising management and execution (AMX) applications.
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.